The evolution of the cosmic molecular gas density

One of the last missing pieces in the puzzle of galaxy formation and evolution through cosmic history is a detailed picture of the role of the cold gas supply in the star-formation process. Cold gas is the fuel for star formation, and thus regulates the buildup of stellar mass, both through the amount of material present through a galaxy's gas mass fraction, and through the efficiency at which it is converted to stars. Over the last decade, important progress has been made in understanding the relative importance of these two factors along with the role of feedback, and the first measurements of the volume density of cold gas out to redshift 4, (the "cold gas history of the Universe") has been obtained. To match the precision of measurements of the star formation and black-hole accretion histories over the coming decades, a two orders of magnitude improvement in molecular line survey speeds is required compared to what is possible with current facilities. Possible pathways towards such large gains include significant upgrades to current facilities like ALMA by 2030 (and beyond), and eventually the construction of a new generation of radio-to-millimeter wavelength facilities, such as the next generation Very Large Array (ngVLA) concept.Comment: 7 pages, 2 figures, Science White paper submitted to Astro2020 Decadal Surve

CO Luminosity Density at High-z (COLDz) Survey: A Sensitive, Large-area Blind Search for Low-J CO Emission from Cold Gas in the Early Universe with the Karl G. Jansky Very Large Array

We describe the CO Luminosity Density at High-z (COLDz) survey, the first spectral line deep field targeting CO(1–0) emission from galaxies at z = 1.95–2.85 and CO(2–1) at z = 4.91–6.70. The main goal of COLDz is to constrain the cosmic density of molecular gas at the peak epoch of cosmic star formation. By targeting both a wide (~51 arcmin2) and a deep (~9 arcmin^2) area, the survey is designed to robustly constrain the bright end and the characteristic luminosity of the CO(1–0) luminosity function. An extensive analysis of the reliability of our line candidates and new techniques provide detailed completeness and statistical corrections as necessary to determine the best constraints to date on the CO luminosity function. Our blind search for CO(1–0) uniformly selects starbursts and massive main-sequence galaxies based on their cold molecular gas masses. Our search also detects CO(2–1) line emission from optically dark, dusty star-forming galaxies at z > 5. We find a range of spatial sizes for the CO-traced gas reservoirs up to ~40 kpc, suggesting that spatially extended cold molecular gas reservoirs may be common in massive, gas-rich galaxies at z ~ 2. Through CO line stacking, we constrain the gas mass fraction in previously known typical star-forming galaxies at z = 2–3. The stacked CO detection suggests lower molecular gas mass fractions than expected for massive main-sequence galaxies by a factor of ~3–6. We find total CO line brightness at ~34 GHz of 0.45 ± 0.2 μK, which constrains future line intensity mapping and CMB experiments

The ALMA Spectroscopic Survey in the HUDF: CO Luminosity Functions and the Molecular Gas Content of Galaxies through Cosmic History

We use the results from the ALMA large program ASPECS, the spectroscopic survey in the Hubble Ultra Deep Field (HUDF), to constrain CO luminosity functions of galaxies and the resulting redshift evolution of ρ(H2). The broad frequency range covered enables us to identify CO emission lines of different rotational transitions in the HUDF at z > 1. We find strong evidence that the CO luminosity function evolves with redshift, with the knee of the CO luminosity function decreasing in luminosity by an order of magnitude from ~2 to the local universe. Based on Schechter fits, we estimate that our observations recover the majority (up to ~90%, depending on the assumptions on the faint end) of the total cosmic CO luminosity at z = 1.0–3.1. After correcting for CO excitation, and adopting a Galactic CO-to-H2 conversion factor, we constrain the evolution of the cosmic molecular gas density ρ(H2): this cosmic gas density peaks at z ~ 1.5 and drops by a factor of ${6.5}_{-1.4}^{+1.8}$ to the value measured locally. The observed evolution in ρ(H2), therefore, closely matches the evolution of the cosmic star formation rate density ρ SFR. We verify the robustness of our result with respect to assumptions on source inclusion and/or CO excitation. As the cosmic star formation history can be expressed as the product of the star formation efficiency and the cosmic density of molecular gas, the similar evolution of ρ(H2) and ρ SFR leaves only little room for a significant evolution of the average star formation efficiency in galaxies since z ~ 3 (85% of cosmic history)

The Evolution of the Baryons Associated with Galaxies Averaged over Cosmic Time and Space

We combine the recent determination of the evolution of the cosmic density of molecular gas (H2) using deep, volumetric surveys, with previous estimates of the cosmic density of stellar mass, star formation rate and atomic gas (H i), to constrain the evolution of baryons associated with galaxies averaged over cosmic time and space. The cosmic H i and H2 densities are roughly equal at z ~ 1.5. The H2 density then decreases by a factor ${6}_{-2}^{+3}$ to today's value, whereas the H i density stays approximately constant. The stellar mass density is increasing continuously with time and surpasses that of the total gas density (H i and H2) at redshift z ~ 1.5. The growth in stellar mass cannot be accounted for by the decrease in cosmic H2 density, necessitating significant accretion of additional gas onto galaxies. With the new H2 constraints, we postulate and put observational constraints on a two-step gas accretion process: (i) a net infall of ionized gas from the intergalactic/circumgalactic medium to refuel the extended H i reservoirs, and (ii) a net inflow of H i and subsequent conversion to H2 in the galaxy centers. Both the infall and inflow rate densities have decreased by almost an order of magnitude since z ~ 2. Assuming that the current trends continue, the cosmic molecular gas density will further decrease by about a factor of two over the next 5 Gyr, the stellar mass will increase by approximately 10%, and cosmic star formation activity will decline steadily toward zero, as the gas infall and accretion shut down

Managing travel fatigue and jet lag in athletes : a review and consensus statement

Athletes are increasingly required to travel domestically and internationally, often resulting in travel fatigue and jet lag. Despite considerable agreement that travel fatigue and jet lag can be a real and impactful issue for athletes regarding performance and risk of illness and injury, evidence on optimal assessment and management is lacking. Therefore 26 researchers and/or clinicians with knowledge in travel fatigue, jet lag and sleep in the sports setting, formed an expert panel to formalise a review and consensus document. This manuscript includes definitions of terminology commonly used in the field of circadian physiology, outlines basic information on the human circadian system and how it is affected by time-givers, discusses the causes and consequences of travel fatigue and jet lag, and provides consensus on recommendations for managing travel fatigue and jet lag in athletes. The lack of evidence restricts the strength of recommendations that are possible but the consensus group identified the fundamental principles and interventions to consider for both the assessment and management of travel fatigue and jet lag. These are summarised in travel toolboxes including strategies for pre-flight, during flight and post-flight. The consensus group also outlined specific steps to advance theory and practice in these areas.https://www.springer.com/journal/402792022-07-14hj2021Sports MedicineStatistic

The evolution of the cosmic molecular gas density

One of the last missing pieces in the puzzle of galaxy formation and evolution through cosmic history is a detailed picture of the role of the cold gas supply in the star-formation process. Cold gas is the fuel for star formation, and thus regulates the buildup of stellar mass, both through the amount of material present through a galaxy's gas mass fraction, and through the efficiency at which it is converted to stars. Over the last decade, important progress has been made in understanding the relative importance of these two factors along with the role of feedback, and the first measurements of the volume density of cold gas out to redshift 4, (the "cold gas history of the Universe") has been obtained. To match the precision of measurements of the star formation and black-hole accretion histories over the coming decades, a two orders of magnitude improvement in molecular line survey speeds is required compared to what is possible with current facilities. Possible pathways towards such large gains include significant upgrades to current facilities like ALMA by 2030 (and beyond), and eventually the construction of a new generation of radio-to-millimeter wavelength facilities, such as the next generation Very Large Array (ngVLA) concept

Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial.

BACKGROUND: Staphylococcus aureus bacteraemia is a common cause of severe community-acquired and hospital-acquired infection worldwide. We tested the hypothesis that adjunctive rifampicin would reduce bacteriologically confirmed treatment failure or disease recurrence, or death, by enhancing early S aureus killing, sterilising infected foci and blood faster, and reducing risks of dissemination and metastatic infection. METHODS: In this multicentre, randomised, double-blind, placebo-controlled trial, adults (≥18 years) with S aureus bacteraemia who had received ≤96 h of active antibiotic therapy were recruited from 29 UK hospitals. Patients were randomly assigned (1:1) via a computer-generated sequential randomisation list to receive 2 weeks of adjunctive rifampicin (600 mg or 900 mg per day according to weight, oral or intravenous) versus identical placebo, together with standard antibiotic therapy. Randomisation was stratified by centre. Patients, investigators, and those caring for the patients were masked to group allocation. The primary outcome was time to bacteriologically confirmed treatment failure or disease recurrence, or death (all-cause), from randomisation to 12 weeks, adjudicated by an independent review committee masked to the treatment. Analysis was intention to treat. This trial was registered, number ISRCTN37666216, and is closed to new participants. FINDINGS: Between Dec 10, 2012, and Oct 25, 2016, 758 eligible participants were randomly assigned: 370 to rifampicin and 388 to placebo. 485 (64%) participants had community-acquired S aureus infections, and 132 (17%) had nosocomial S aureus infections. 47 (6%) had meticillin-resistant infections. 301 (40%) participants had an initial deep infection focus. Standard antibiotics were given for 29 (IQR 18-45) days; 619 (82%) participants received flucloxacillin. By week 12, 62 (17%) of participants who received rifampicin versus 71 (18%) who received placebo experienced treatment failure or disease recurrence, or died (absolute risk difference -1·4%, 95% CI -7·0 to 4·3; hazard ratio 0·96, 0·68-1·35, p=0·81). From randomisation to 12 weeks, no evidence of differences in serious (p=0·17) or grade 3-4 (p=0·36) adverse events were observed; however, 63 (17%) participants in the rifampicin group versus 39 (10%) in the placebo group had antibiotic or trial drug-modifying adverse events (p=0·004), and 24 (6%) versus six (2%) had drug interactions (p=0·0005). INTERPRETATION: Adjunctive rifampicin provided no overall benefit over standard antibiotic therapy in adults with S aureus bacteraemia. FUNDING: UK National Institute for Health Research Health Technology Assessment